Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.270 -0.030 (-2.31%)

Streaming Delayed Price Updated: 3:28 PM EDT, May 22, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	50,916
Open	1.300
Bid (Size)	1.260 (200)
Ask (Size)	1.290 (1,000)
Prev. Close	1.300
Today's Range	1.240 - 1.300
52wk Range	1.050 - 3.100
Shares Outstanding	34,380,971
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Preclinical Data Supporting Telomir-Zn in Wilson’s Disease

May 20, 2026

Via Investor Brand Network

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

May 20, 2026

Via ACCESS Newswire

Performance

YTD	-5.2%	-5.2%
1 Month	-8.6%	-8.6%
3 Month	+12.4%	+12.4%
6 Month	-8.6%	-8.6%
1 Year	-40.4%	-40.4%

More News

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer

April 30, 2026

Via Investor Brand Network

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

April 30, 2026

Via ACCESS Newswire

MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Closes TELI Acquisition, Secures Global Rights to Telomir-1

April 24, 2026

Via Investor Brand Network

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

April 24, 2026

Via ACCESS Newswire

InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Submits IND for TNBC Candidate Telomir-1

March 31, 2026

Via Investor Brand Network

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

March 31, 2026

Via ACCESS Newswire

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models

February 17, 2026

Via Investor Brand Network

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

February 17, 2026

Via ACCESS Newswire

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn

February 05, 2026

Via Investor Brand Network

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

February 05, 2026

Via ACCESS Newswire

MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Positive Telomir-1 Results In TNBC Zebrafish Xenograft Study

January 05, 2026

Via Investor Brand Network

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

January 05, 2026

Via ACCESS Newswire

InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1

December 18, 2025

Via Investor Brand Network

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

December 18, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

November 25, 2025

Via ACCESS Newswire

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death ↗

November 21, 2025

Via Stocktwits

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

November 21, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

November 12, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

October 23, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

October 21, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

October 14, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 09, 2025

Via Benzinga

Thursday's after hours session: top gainers and losers ↗

October 09, 2025

Via Chartmill

Frequently Asked Questions

Is Telomir Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Telomir Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Telomir Pharmaceuticals, Inc. - Common Stock trade on?

Telomir Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock is TELO on the Nasdaq Stock Market

What is the current price of Telomir Pharmaceuticals, Inc. - Common Stock?

The current price of Telomir Pharmaceuticals, Inc. - Common Stock is 1.270

When was Telomir Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Telomir Pharmaceuticals, Inc. - Common Stock was at 05/22/26 03:28 PM ET

What is the market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock is 43.66M

How many shares of Telomir Pharmaceuticals, Inc. - Common Stock are outstanding?

Telomir Pharmaceuticals, Inc. - Common Stock has 44M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.